210 related articles for article (PubMed ID: 4668639)
1. Proceedings: Effect of amantadine on the urinary excretion of some monoamines and metabolites in normal and parkinsonian subjects.
Jones DG; Lenman JA; Robertson MA; Turnbull MJ
Br J Pharmacol; 1972 Feb; 44(2):386P-387P. PubMed ID: 4668639
[No Abstract] [Full Text] [Related]
2. Effect of amantadine on the urinary excretion of some monoamines and metabolites in normal and Parkinsonian subjects.
Jones DG; Turnbull MJ; Lenman JA; Robertson MA
J Neurol Sci; 1972 Nov; 17(3):245-53. PubMed ID: 4653961
[No Abstract] [Full Text] [Related]
3. Responses of the urinary excretion of homovanillic acid and of 5-hydroxy-indol-acetic acid to treatment with L-dopa and amantadine.
Molnár G; Fodor A
Ther Hung; 1973; 21(1):35-40. PubMed ID: 4792890
[No Abstract] [Full Text] [Related]
4. [The effect of alpha-DOPA on the dynamics of urinary excretion of DOPA, catecholamines and their metabolites in healthy subjects and in patients with parkinsonism].
Matlina ESh; Kandel' EI; Vasil'ev VN; Iadgarov IS; Bol'shakova TD
Zh Nevropatol Psikhiatr Im S S Korsakova; 1973; 73(2):205-9. PubMed ID: 4743269
[No Abstract] [Full Text] [Related]
5. Urinary monoamine metabolite excretion in disorders of movement. Effects of amantadine and levodopa.
Lenman JA; Turnbull MJ; Reid A; Fleming AM
J Neurol Sci; 1977 Jun; 32(2):219-25. PubMed ID: 874521
[TBL] [Abstract][Full Text] [Related]
6. [Catecholamine excretion and treatment of parkinsonism with midantan].
Kandel' EI; Iadgarov IS
Zh Nevropatol Psikhiatr Im S S Korsakova; 1976 Sep; 76(9):1323-6. PubMed ID: 1015136
[No Abstract] [Full Text] [Related]
7. Urinary excretion of dopamine and homovanillic acid during L-dopa treatment of Parkinson's disease.
Streifler M; Vardi Y; Kesten M; Oberman Z; Herzberg M
Isr J Med Sci; 1972 May; 81(5):597-601. PubMed ID: 5042950
[No Abstract] [Full Text] [Related]
8. Effect of cannabis sativa administered by smoking on biogenic amine excretion in man.
Messiha FS; Soskin RA
Res Commun Chem Pathol Pharmacol; 1973 Jul; 6(1):325-8. PubMed ID: 4734006
[No Abstract] [Full Text] [Related]
9. Dose-related alterations in metabolism of levodopa: possible mechanism for hypotensive effect.
Kochar MS; Itskovitz HD; Sasse EA; Baker JD; Doumas BT
J Clin Pharmacol; 1974; 14(8):448-54. PubMed ID: 4851433
[No Abstract] [Full Text] [Related]
10. Imipramine-mediated effects on levodopa metabolism in man.
Messiha FS; Morgan JP
Biochem Pharmacol; 1974 May; 23(10):1503-7. PubMed ID: 4847533
[No Abstract] [Full Text] [Related]
11. Decreased dopamine and homovanillic acid excretion in a case with chlorpromazine-induced Parkinsonism.
Messiha FS; Turek I
Res Commun Chem Pathol Pharmacol; 1973 Jul; 6(1):329-30. PubMed ID: 4734007
[No Abstract] [Full Text] [Related]
12. [Dopamine in essential arterial hypertension: excretion of its metabolite homovanillic acid].
Chávez Lara B; Serrano PA; Sánchez Torres G; Chávez Domínguez R
Arch Inst Cardiol Mex; 1975; 45(1):77-81. PubMed ID: 1130915
[TBL] [Abstract][Full Text] [Related]
13. Metabolic patterns and clinical response to levedopa therapy in Parkinson's disease.
Messiha FS; Knopp W
Clin Pharmacol Ther; 1973; 14(4):565-71. PubMed ID: 4541856
[No Abstract] [Full Text] [Related]
14. Use of alumina, sephadex G10, and ion-exchange columns to purify samples for determination of epinephrine, norepinephrine, dopamine, homovanillic acid, and 5-hydroxyindoleacetic acid in urine.
Westerink BH; Bosker FJ; O'Hanlon JF
Clin Chem; 1982 Aug; 28(8):1745-8. PubMed ID: 6178533
[TBL] [Abstract][Full Text] [Related]
15. Development of a screening test for L-dopa and its metabolites in urine.
Routh JI; Bannow RE
Clin Chem; 1971 Sep; 17(9):872-4. PubMed ID: 5571486
[No Abstract] [Full Text] [Related]
16. Separation and determination of urinary homovanillic acid and iso-homovanillic acid by gas-liquid chromatography and electron capture detection.
Dziedzic SW; Dziedzic LB; Gitlow SE
J Lab Clin Med; 1973 Nov; 82(5):829-35. PubMed ID: 4746822
[No Abstract] [Full Text] [Related]
17. Excretion of L-dopa and its metabolites in urine of Parkinson's disease patients receiving L-dopa therapy.
Routh JI; Bannow RE; Fincham RW; Stoll JL
Clin Chem; 1971 Sep; 17(9):867-71. PubMed ID: 5571485
[No Abstract] [Full Text] [Related]
18. Biochemical investigations in Parkinsonism. A study of the metabolites of the biogenic amines in the lumbar CSF.
Pullar IA; Dowson JH; Ahmed R; Chow R; Gillingham FJ
Confin Neurol; 1972; 34(2):143-8. PubMed ID: 4666057
[No Abstract] [Full Text] [Related]
19. A study of biogenic amine metabolites in the cerebrospinal fluid and urine of monkeys with chlorpromazine-induced dyskinesia.
Messiha FS
J Neurol Sci; 1974 Jan; 21(1):39-46. PubMed ID: 4216622
[No Abstract] [Full Text] [Related]
20. Day-to-day intraindividual reliability and interindividual differences in monoamines excretion.
Curtin F; Walker JP; Schulz P
J Affect Disord; 1996 Jun; 38(2-3):173-8. PubMed ID: 8791186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
